Acrux stuck in the twilight zone

Acrux has come under further pressure after United States regulators voiced concerns about the safety of testosterone treatments.

The once darling of the biotech world has been condemned to walk with the living dead for some months at least after United States regulators voiced concerns about the safety of testosterone treatments.

The news sent Acrux (ACR) plummeting another 7.9% to a near four-year low of $1.91 this afternoon following yesterday’s 10.3% crash. The two-session loss is the biggest since August 2012 and the forth worst fall on record for stock.

{{content.question}}

SMS Code Sent…

Hi {{ user.FirstName }}

Looks like you've already taken a free trial

Please enter your payment details

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

If you didn't receive SMS code please

Looks you are already a member. Please enter your password to proceed

Please untick this box when using a public or shared device


Verify your mobile number to unlock a FREE trial

Please sign up for full access

Updating information

Please wait ...

  • Mastercard
  • Visa

Related Articles